MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-? Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

Stock Information for Eton Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Eton Pharmaceuticals Inc.

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD(TM), Reduced Acute Inflammatory Pain
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-? Market Disrupter, at BioFuture 2023
FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-? inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.